The MRD4U assay represents a new personalized liquid biopsy technique designed to monitor central nervous system tumors in children with high sensitivity. This development may enable earlier detection of tumor recurrence and better treatment response assessment in pediatric oncology, marking a milestone in non-invasive cancer diagnostics as published in BMC Cancer.